Jiangsu NHWA Pharmaceutical Co., Ltd.
Industry
- Pharmaceuticals
- Distributors
Other Names/Subsidiaries
- Jiangsu NHWA Pharmaceutical
Latest on Jiangsu NHWA Pharmaceutical Co., Ltd.
Initial public offerings in the US are in a slump, with just nine biopharmaceutical company IPOs during the first quarter, raising a total of $807m. The Q1 tally is a fraction of the offerings and the
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seagen, RemeGen Partner Outside Asia, E
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Jan. 9-24. Deal Watc
Mergers & Acquisitions /In Vitro Diagnostics Clovis Oncology Inc. Roche Roche Diagnostics Roche Molecular Systems Inc. On the same day it received rights to a solid tumor compound from Pfizer Inc.